The Next Frontier in Biotechnology- How Smart Money Invests in the Psychedelic Sector
Featured expert presenters are Peter Reitano, who will be talking about “Beyond the medicalization of Psychedelics: the next big investment opportunity is the consumer” and Gregg Peterson will be addressing “What Intellectual Property in this space is truly differentiating, and protects a company’s asset? You might be surprised..,”
- (1888PressRelease) September 18, 2021 - Therapeutic Applications of Psychedelics-assisted Treatments for Depression and Anxiety.
The Conscious Fund Caribbean — A Global Venture Fund Courting Bermuda's Asset Managements & Angel VC, to explore investing in Psychedelic Technology. A FREE live webinar on September 30th, 2021, from 12 to 1:30 PM (ADT). As a centre of financial services and capital management, Bermuda is an early entrant in new investing trends and is an ideal launchpad for biotech and pharmaceutical investments. Companies with international centres use the Caribbean region as a hub for financial and intellectual property holdings. This live event is dedicated to high net-worth asset management and consultants, family offices, entrepreneurs, and angel investors.
When the psychedelic market first appeared, many serious investors were skeptical –newcomers wondering exactly how legal this new industry is — and whether now is the time to put money into it. Jacqueline Lopez, a business consultant with extensive experience operating in Bermuda, has partnered with Henri Sant-Cassia, founding partner of The Conscious Fund, to host a live webinar. Lopez’s life partner, a multiple-cancer survivor, found relief from the existential angst using psilocybin.
The latest results from a clinical trial to treat PTSD (post-traumatic stress disorder) showed the promise of a stigmatized drug (MDMA) to treat anxiety and depression at a time when Covid-19 has raised global awareness of the toll of mental health conditions. Research is targeting treatment markets such as traumatic brain injury, cognitive decline, and microdosing experiments also reported beneficial outcomes, non-scientific, however.
Investing in the next evolution of mental health care is an honorable endeavor, to be sure. However, it would be dishonest to suggest that this is just about altruism. “The truth is, while providing the best-in-breed psychedelics companies with the early-stage capital necessary to bring these treatments to market, the potential returns on these investments are really what’s bringing most investors and business leaders to the table. Some notable companies include: CompassPathways (UK), Mind Medicine, Numinus Wellness (both from Canada), and The Beckley Foundation (UK)” conclude Lopez.
Presenters include industry experts Peter Reitano, who will be talking about “Beyond the Medicalization of Psychedelics: the next big investment opportunity is the consumer,” and Gregg Peterson will be addressing “What Intellectual Property in this space is truly differentiating, and protects a company’s asset? You might be surprised..” followed by a Q&A. Reserve your space HERE.
The Conscious Fund is the most active early-stage venture fund in the psychedelic medicine space. It invests in drug discovery, clinics, addiction programs, retreats, AI, telemedicine, media, and training. Its global, platform-based approach helps transform outcomes for patients with mental health, addiction, and chronic pain issues. The $60M fund has backed 21 of the leading companies in the sector, spanning drug discovery, clinics, addiction, AI, and media, and has incubated 13 projects including The Psychedelic Medicine Association, the first psychedelic medicine SPAC and media leader Microdose, one of the first profitable companies in the industry. Find out more about https://theconscious.fund
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam